Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2011

Conditions
Immune Thrombocytopenic Purpura
Interventions
DRUG

Sym001

Each cohort will receive one single dose of Sym001 according the assigned dose level.

Trial Locations (59)

2100

Clinical center Vojvodina 3801, Novi Sad

11080

Clinical Center Zemun 3803, Zemun

18000

Clinical Center Nis 3802, Niš

19104

Hospital of the University of Pennsylvania, Site 1002, Philadelphia

21018

Vinnytsya Regional Clinical Hospital, 3902, Vinnytsia

22100

Western Galilee - Nahariya Hospital, 9722, Nahariya

29000

Khmelnytskyi Regional Hospital, 3903, Khmelnytskyi

29414

2085 Henry Tecklenburg Drive, 1001, Charleston

31048

Bnai-Zion Medical Center, 9721, Haifa

35254

Rambam Medical Center, 9723, Haifa

49100

Rabin Medical Center, 9724, Petah Tikva

58100

The Edith Wolfson Medical Center, 9725, Holon

64239

Tel-Aviv Sourasky Medical Center, 9726, Tel Aviv

83045

Gusak Academy of AMS Ukraine, 3905, Donetsk

180009

Cherkassy regional oncology center, 3906, Cherkassy

198205

Saint Petersburg State Institution Of Healthcare, 7001, Saint Petersburg

300053

State Healthcare Institution Tula Regional Clin. Hosp., 7002, Tula

443095

Regional Clinical Hospital na MI Kalinin, 7005, Samara

500033

Apollo Hospital, 9104, Hyderabad

560034

St. John's Medical College Hospital, 9106, Bangalore

560054

MS Ramaiah Memorial Hospital, 9108, Bangalore

560099

Narayana Hrudayalaya Hospitals, 9105, Bangalore

576104

Columbia Asia Referral Hospital-Yeshwanthpur, 9101, Bangalore

Kasturba Medical College Hospital, 9103, Udupi

600010

Aysha Hospital Pvt. Ltd., 9109, Chennai

603126

Regional Clinical Hospital of Nizhny Novgorod, 7003, Nizhny Novgorod

68198-7680

Univ Nebraska Med Ctr. UNMC, 1005, Omaha

Unknown

Research Site 3203, Bruges

Research Site 3202, Leuven

Research Site 3201, Yvoir

Research Site 4906, 4907, Berlin

Research Site 4902, Cologne

Research Site 4903, Duisburg

Research Site 4905, Essen

Reseach Site 4908, Halle

Research Site 4901, Hanover

Research Site 4904, Regensburg

Research site 4801, Gdansk

Research Site 4806, Krakow

Research Site 4805, Lodz

Instytut Hematologii i Transfuzjologii, 4807, Warsaw

Research Site 4802, 4808, Warsaw

Research Site 4803, Warszava

Research Site 4804, Wroclaw

Brasov Country Hospital, 4002, Brasov

Institutul Clinic Fundeni, 4003, Bucharest

"Prof. Dr. Ion Chiricuta Oncolgy Institute, 4001", Cluj-Napoca

Spitalul Clinic de Urgente Sfantu Spiridon, 4004, Iași

Reseach Site 3403, Barcelona

Hospital Gregorio Maranon, 3405, Madrid

Hospital La Princesa, 3404, Madrid

Research Site 3401, Madrid

Research Site 3402, Valencia

04112

City Hospital #9 Kyiv Clinical Hospital, 3904, Kiev

LS9 7TF

St. James's University Hospital, 4403, Leeds

W12 OHS

Hammersmith Hosptial, 4402, London

WC1E 6HX

University College, 4401, London

NE1 4LP

Royal Victoria Infirmery, 4404, Newcastle upon Tyne

SA2 8QL

Singleton Hospital, 4405, Swansea

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Symphogen A/S

INDUSTRY